granulomatosis with polyangiitis and microscopic polyangiitis
Immunology · 2015–2024
3decisions
2medicines
3carried consumer input
23individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| avacopan Treatment of severe active granulomatosis with polyangiitis (GPA) and severe active microscopic polyangiitis (MPA) in combination with rituximab or… | Mar 2024 | Recommended with restriction | 17 individuals Australian Rheumatology Association |
| avacopan Treatment of severe active granulomatosis with polyangiitis (GPA) and severe active microscopic polyangiitis (MPA) in combination with rituximab or… | Jul 2023 | Not recommended | input received Australian Rheumatology Association |
| rituximab Remission induction in patients with severe active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) who are contraindicated or… | Jul 2015 | Deferred | 6 individuals |
Who spoke
Australian Rheumatology Association
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.